导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.49% | 1378/4773 |
| 近一周 | -1.49% | 478/5462 |
| 近一月 | -0.32% | 777/5421 |
| 近一季 | -1.00% | 921/5209 |
| 近半年 | 3.87% | 862/4920 |
| 近一年 | -0.69% | 2763/4366 |
| 近两年 | 47.69% | 1552/2954 |
| 近三年 | 56.09% | 486/2253 |
| 成立以来 | 54.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.75% 1458/4961 |
-6.17% 3666/5312 |
- - |
- - |
| 2025 | 22.11% 1998/4813 |
12.05% 258/3635 |
2.49% 1540/4076 |
11.73% 3135/4524 |
-4.83% 3487/4813 |
| 2024 | 22.77% 368/3463 |
-0.41% 1111/2808 |
11.84% 26/3014 |
4.92% 2886/3129 |
5.07% 646/3463 |
| 2023 | 5.32% 191/2656 |
3.74% 1136/2280 |
4.52% 81/2385 |
-5.07% 1276/2515 |
2.32% 66/2655 |
| 2022 | 1.82% 29/2207 |
1.65% 98/1919 |
3.91% 1076/2016 |
-8.03% 162/2113 |
4.81% 506/2208 |
| 2021 | 6.33% 517/1822 |
10.10% 50/1255 |
0.66% 1087/1330 |
-1.22% 510/1466 |
-2.87% 1424/1822 |
| 2020 | -11.58% 993/1250 |
-13.77% 939/1028 |
-1.80% 1032/1067 |
-3.67% 1095/1164 |
8.41% 673/1184 |
| 2019 | - - |
- - |
- - |
- - |
4.05% 819/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 太平MSCI香港价值增强A VS. 长安沪深300非周期A(740101) |